In August 2022, olipudase alfa (Xenpozyme), a hydrolytic lysosomal sphingomyelin-specific enzyme indicated for non–CNS manifestations of acid sphingomyelinase deficiency (ASMD), was approved in the US and Europe. This Premium deep dive into Xenpozyme includes: the industry context, the clinical data, the target rationale, the mechanism of [...]